Development and validation a radiomics nomogram for predicting thymidylate synthase status in hepatocellular carcinoma based on Gd-DTPA contrast enhanced MRI.
Hepatocellular carcinoma
Nomogram
Radiomics
Thymidylate synthase
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
17 Oct 2023
17 Oct 2023
Historique:
received:
05
07
2022
accepted:
21
06
2023
medline:
23
10
2023
pubmed:
18
10
2023
entrez:
17
10
2023
Statut:
epublish
Résumé
The purpose of this study was to develop and validate a radiomics nomogram for predicting thymidylate synthase (TYMS) status in hepatocellular carcinoma (HCC) by using Gd-DTPA contrast enhanced MRI. We retrospectively enrolled 147 consecutive patients with surgically confirmed HCC and randomly allocated to training and validation set (7:3). The TYMS status was immunohistochemical determined and classified into low TYMS (positive cells ≤ 25%) and high TYMS (positive cells > 25%) groups. Radiomics features were extracted from the arterial phases and portal venous phase of Gd-DTPA contrast enhanced MRI. Least absolute shrinkage and selection operator (LASSO) were applied for generating the Rad score. Clinical data and MRI findings were assessed to build a clinical model. Rad score combined with clinical features was used to construct radiomics nomogram. A total of 2260 features were extracted and reduced to 7 features as the most important discriminators to build the Rad score. InAFP was identified as the only independent clinical factors for TYMS status. The radiomics nomogram showed good discrimination in training (AUC, 0.759; 95% CI 0.665-0.838) and validation set (AUC, 0.739; 95% CI 0.585-0.860), and showed better discrimination capability (P < 0.05) compared with clinical model in training (AUC, 0.656; 95% CI 0.555-0.746) and validation set (AUC, 0.622; 95% CI 0.463-0.764). The radiomics nomogram shows favorable predictive efficacy for TYMS status in HCC, which might be helpful for the personalized treatment of HCC.
Identifiants
pubmed: 37848807
doi: 10.1186/s12885-023-11096-7
pii: 10.1186/s12885-023-11096-7
pmc: PMC10580573
doi:
Substances chimiques
Gadolinium DTPA
K2I13DR72L
Thymidylate Synthase
EC 2.1.1.45
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
991Subventions
Organisme : Science and Technology Planning Project of Fuzhou
ID : 2020-WS-106
Organisme : Science and Technology Planning Project of Fuzhou
ID : 2020-WS-106
Organisme : Science and Technology Planning Project of Fuzhou
ID : 2020-WS-106
Organisme : Science and Technology Planning Project of Fuzhou
ID : 2020-WS-106
Organisme : Science and Technology Planning Project of Fuzhou
ID : 2020-WS-106
Organisme : Science and Technology Planning Project of Fuzhou
ID : 2020-WS-106
Organisme : Science and Technology Planning Project of Fuzhou
ID : 2020-WS-106
Organisme : Science and Technology Planning Project of Fuzhou
ID : 2020-WS-106
Organisme : Science and Technology Planning Project of Fuzhou
ID : 2020-WS-106
Organisme : Science and Technology Planning Project of Fuzhou
ID : 2020-WS-106
Organisme : Science and Technology Planning Project of Fuzhou
ID : 2020-WS-106
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Kulik L, El-Serag HB. Epidemiology and management of Hepatocellular Carcinoma. Gastroenterology. 2019;156(2):477–491e1.
doi: 10.1053/j.gastro.2018.08.065
pubmed: 30367835
Su Z, Liu G, Fang T, et al. Silencing MRP1-4 genes by RNA interference enhances sensitivity of human hepatoma cells to chemotherapy. Am J Transl Res. 2016;8(6):2790–802.
pubmed: 27398162
pmcid: 4931173
Van Triest B, Pinedo HM, Giaccone G, Peters GJ. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol. 2000;11(4):385–91.
doi: 10.1023/A:1008351221345
pubmed: 10847455
Watt PM, Hickson ID. Structure and function of type II DNA topoisomerases. Biochem J. 1994;303(Pt 3):681–95.
doi: 10.1042/bj3030681
pubmed: 7980433
pmcid: 1137600
Chen R, Cheng Q, Owusu-Ansah KG, et al. Cabazitaxel, a novel chemotherapeutic alternative for drug-resistant hepatocellular carcinoma. Am J Cancer Res. 2018;8(7):1297–306.
pubmed: 30094102
pmcid: 6079161
Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 2010;10(3):194–204.
doi: 10.1038/nrc2803
pubmed: 20147901
Carreras CW, Santi DV. The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem. 1995;64:721–62.
doi: 10.1146/annurev.bi.64.070195.003445
pubmed: 7574499
Mirjolet JF, Barberi-Heyob M, Merlin JL, et al. Thymidylate synthase expression and activity: relation to S-phase parameters and 5-fluorouracil sensitivity. Br J Cancer. 1998;78(1):62–8.
doi: 10.1038/bjc.1998.443
pubmed: 9662252
pmcid: 2062951
van Triest B, Pinedo HM, van Hensbergen Y, et al. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res. 1999;5(3):643–54.
pubmed: 10100718
Mizutani Y, Wada H, Yoshida O, et al. Significance of thymidylate synthase activity in renal cell carcinoma. Clin Cancer Res. 2003;9(4):1453–60.
pubmed: 12684419
Wang X, Sun X, Du X, et al. Thymidylate synthase gene polymorphisms as important contributors affecting hepatocellular carcinoma prognosis. Clin Res Hepatol Gastroenterol. 2017;41(3):319–26.
doi: 10.1016/j.clinre.2016.10.012
pubmed: 28043790
Segal E, Sirlin CB, Ooi C, et al. Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol. 2007;25(6):675–80.
doi: 10.1038/nbt1306
pubmed: 17515910
Kuo MD, Gollub J, Sirlin CB, Ooi C, Chen X. Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma. J Vasc Interv Radiol. 2007;18(7):821–31.
doi: 10.1016/j.jvir.2007.04.031
pubmed: 17609439
Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350:g7594.
doi: 10.1136/bmj.g7594
pubmed: 25569120
Ding Z, Lin K, Fu J, et al. An MR-based radiomics model for differentiation between hepatocellular carcinoma and focal nodular hyperplasia in non-cirrhotic liver. World J Surg Oncol. 2021;19(1):181.
doi: 10.1186/s12957-021-02266-7
pubmed: 34154624
pmcid: 8215802
DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–45.
doi: 10.2307/2531595
pubmed: 3203132
Huang Y, Liu Z, He L, et al. Radiomics signature: a potential biomarker for the prediction of Disease-Free Survival in early-stage (I or II) Non-Small Cell Lung Cancer. Radiology. 2016;281(3):947–57.
doi: 10.1148/radiol.2016152234
pubmed: 27347764
Peng J, Zhang J, Zhang Q, Xu Y, Zhou J, Liu L. A radiomics nomogram for preoperative prediction of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma. Diagn Interv Radiol. 2018;24(3):121–7.
doi: 10.5152/dir.2018.17467
pubmed: 29770763
pmcid: 5951199
Zhou Y, He L, Huang Y, et al. CT-based radiomics signature: a potential biomarker for preoperative prediction of early recurrence in hepatocellular carcinoma. Abdom Radiol (NY). 2017;42(6):1695–704.
doi: 10.1007/s00261-017-1072-0
pubmed: 28180924
Li W, Liu K, Chen Y, Zhu M, Li M. Role of alpha-fetoprotein in Hepatocellular Carcinoma Drug Resistance. Curr Med Chem. 2021;28(6):1126–42.
doi: 10.2174/0929867327999200729151247
pubmed: 32729413
Patt YZ, Yoffe B, Charnsangavej C, et al. Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b. Cancer. 1993;72(9):2574–82.
doi: 10.1002/1097-0142(19931101)72:9<2574::AID-CNCR2820720911>3.0.CO;2-L
pubmed: 7691392
Wang Y, Chen Y, Ge N, et al. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization. Ann Surg Oncol. 2012;19(11):3540–6.
doi: 10.1245/s10434-012-2368-5
pubmed: 22532305
Yamasaki T, Kimura T, Kurokawa F, et al. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J Gastroenterol. 2005;40(1):70–8.
doi: 10.1007/s00535-004-1494-7
pubmed: 15692792
Wei L, Wang X, Lv L, et al. The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma. Mol Cancer. 2019;18(1):147.
doi: 10.1186/s12943-019-1086-z
pubmed: 31651347
pmcid: 6814027